Teclistamab: Earlier Use in Myeloma – Dr. Roberto Mina’s Insights

The landscape of treatment for multiple myeloma is shifting, with emerging evidence suggesting that teclistamab, a relatively new immunotherapy, could play a role much earlier in the disease course than previously thought. Recent findings from the phase 3 MajesTEC-9 trial, highlighted by hematologist Roberto Mina, MD, demonstrate significant improvements in progression-free survival when teclistamab is combined with daratumumab, compared to standard treatment regimens. This signals a potential paradigm shift in how we approach myeloma, particularly for patients who have experienced one to three prior lines of therapy.

Understanding Multiple Myeloma and Current Treatment Approaches

Multiple myeloma is a cancer that originates in plasma cells, a type of white blood cell responsible for producing antibodies. These cancerous plasma cells accumulate in the bone marrow, interfering with the production of healthy blood cells and leading to a range of complications, including bone pain, fatigue and increased susceptibility to infection. The National Cancer Institute provides comprehensive information on the disease.

Historically, treatment for multiple myeloma has relied on chemotherapy, stem cell transplantation, and more recently, immunotherapies like daratumumab, a monoclonal antibody targeting the CD38 protein found on myeloma cells. Although these treatments can be effective, many patients eventually experience relapse or grow refractory to therapy, necessitating new approaches. The standard of care for relapsed/refractory myeloma often involves combinations of drugs like pomalidomide or bortezomib with dexamethasone.

MajesTEC-9 Trial: A Significant Step Forward

The MajesTEC-9 trial, a randomized phase 3 study, directly compared the efficacy of teclistamab combined with daratumumab to daratumumab combined with either pomalidomide and dexamethasone (DPd) or bortezomib and dexamethasone (DVd). The trial enrolled 587 patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The primary endpoint was progression-free survival – the length of time patients lived without their disease worsening.

The results, published in the New England Journal of Medicine in December 2025, were compelling. At a median follow-up of 34.5 months, progression-free survival was significantly longer in the teclistamab-daratumumab group (83.4%) compared to the DPd or DVd group (29.7%). This translated to a hazard ratio of 0.17, indicating a substantial reduction in the risk of disease progression. Patients receiving the teclistamab combination experienced significantly higher rates of complete response or better (81.8% vs. 32.1%), overall response (89.0% vs. 75.3%), and minimal residual disease negativity (58.4% vs. 17.1%).

How Teclistamab Works: A Novel Immunotherapy Approach

Teclistamab is a bispecific antibody, meaning it’s engineered to bind to two different targets simultaneously. In this case, it targets CD3, a protein found on the surface of T-cells (immune cells), and B-cell maturation antigen (BCMA), a protein expressed on myeloma cells. By bridging these two targets, teclistamab effectively redirects T-cells to recognize and kill myeloma cells. This mechanism of action harnesses the power of the patient’s own immune system to fight the cancer.

Adverse Events and Safety Considerations

While the MajesTEC-9 trial demonstrated remarkable efficacy, it’s crucial to acknowledge the potential for adverse events. Serious adverse events occurred in 70.7% of patients in the teclistamab-daratumumab group, compared to 62.4% in the DPd or DVd group. Deaths attributed to adverse events were slightly higher in the teclistamab group (7.1%) than in the DPd/DVd group (5.9%). These findings underscore the importance of careful monitoring and management of potential side effects, which can include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

What Does This Mean for Patients?

The MajesTEC-9 trial results suggest that teclistamab, in combination with daratumumab, could become a new standard of care for patients with relapsed or refractory multiple myeloma, even those who have received only one to three prior lines of therapy. This is a significant advancement, as it offers a highly effective treatment option for patients who may not have benefited from traditional approaches. However, it’s critical to remember that this is a complex disease, and treatment decisions should be made on an individual basis, in consultation with a qualified hematologist-oncologist.

Looking Ahead: Ongoing Research and Future Directions

The positive results from MajesTEC-9 are likely to spur further research into the use of teclistamab in earlier lines of therapy for multiple myeloma. Researchers are also exploring the potential of combining teclistamab with other immunotherapies and targeted agents to further enhance its efficacy. Dr. Roberto Mina, a key investigator in the MajesTEC-9 trial, believes these findings represent a transformative step in myeloma care. Ongoing surveillance will be critical to monitor long-term outcomes and identify any potential late effects of teclistamab therapy. Further studies will also be needed to determine the optimal duration of treatment and to identify biomarkers that can predict which patients are most likely to benefit from this innovative immunotherapy.

The evolving treatment landscape for multiple myeloma offers renewed hope for patients and underscores the importance of continued research and innovation in the fight against this challenging cancer.